Busulfan
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Transplantation Conditioning
Myeloablative Agonists
Bone Marrow Transplantation
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Hepatic Veno-Occlusive Disease
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Transplantation, Homologous
Vidarabine
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Graft vs Host Disease
Whole-Body Irradiation
Alkylating Agents
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Transplantation, Autologous
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Melphalan
Thiotepa
Graft Survival
Hematologic Neoplasms
Drug Monitoring
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Spermatogonia
Histocompatibility
Transplantation Chimera
Oogonia
Myelodysplastic Syndromes
Combined Modality Therapy
Antilymphocyte Serum
Antineoplastic Combined Chemotherapy Protocols
Pharmaceutical Solutions
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Seminiferous Tubules
Lactobacillus acidophilus
Aminocaproic Acid
Aminocaproates
Amphotericin B
Antifibrinolytic Agents
Lactobacillus
Encyclopedias as Topic
Poliovirus Vaccine, Oral
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
Poliovirus Vaccine, Inactivated
Poliovirus
A species of ENTEROVIRUS which is the causal agent of POLIOMYELITIS in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.
Pulmonary Veno-Occlusive Disease
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Pulmonary Fibrosis
Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (1/594)
Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle. (+info)High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. (2/594)
We explored the combination of busulfan/cyclophosphamide/etoposide as conditioning regimen prior to bone marrow transplantation in 31 patients with acute myeloid leukemia (AML) in first complete remission. The preparative regimen consisted of 16 mg/kg busulfan, 30-60 mg/kg VP-16, and 120 mg/kg cyclophosphamide. With a median follow-up of 30.5 months (range, 5-60 months), 25 patients are alive in continuous complete remission. Estimated disease-free survival at 5 years is 80.5%. Death was due to transplant-related toxicity (graft-versus-host disease and cytomegalovirus infection, graft-versus-host disease and pneumonia, sepsis and mucositis, respectively). None of the patients have relapsed. As demonstrated by the results of this analysis, the conditioning regimen busulfan/cyclophosphamide/etoposide is effective and well tolerated in patients with AML in first complete remission. Main nonhematological toxicities were mucositis and hepatotoxicity. The low mortality and relapse rate appears to justify allogeneic bone marrow transplantation for patients with AML in first complete remission who have an HLA-identical donor. Whether this regimen offers a substantial improvement in disease-free and overall survival over presently used regimens warrants further investigation. (+info)Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. (3/594)
High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing's sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts. Because busulphan is highly insoluble in water, the use of several vehicles for enteral and parenteral administration was first investigated in terms of pharmacokinetics and toxicity. The highest bioavailability was obtained with busulphan in DMSO administered i.p. When busulphan was suspended in carboxymethylcellulose and given orally or i.p., the bioavailability was poor. Then, in the therapeutic experiments, busulphan in DMSO was administered i.p. on days 0 and 4. At the maximum tolerated total dose (50 mg kg(-1)), busulphan induced a significant tumour growth delay, ranging from 12 to 34 days in the three neuroblastomas evaluated and in one out of three medulloblastomas. At a dose level above the maximum tolerated dose, busulphan induced complete and partial tumour regressions. Busulphan was inactive in a peripheral primitive neuroectodermal tumour (PNET) xenograft. When busulphan pharmacokinetics in mice and humans were considered, the estimated systemic exposure at the therapeutically active dose in mice (113 microg h ml(-1)) was close to the mean total systemic exposure in children receiving high-dose busulphan (102.4 microg h ml(-1)). In conclusion, busulphan displayed a significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at plasma drug concentrations which can be achieved clinically in children receiving high-dose busulphan-containing regimens. (+info)Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (4/594)
We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis. (+info)Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. (5/594)
Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases. We report successful allogeneic bone marrow transplantation in two siblings with this disease from their sister, and their long term follow-up. We used reduced doses of cyclophosphamide and busulfan for conditioning instead of total body irradiation. Also, we report late adverse effects of transplantation which are not distinguishable from the natural course of disease. (+info)Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. (6/594)
Leukemic patients receiving marrow from HLA-identical sibling donors were randomized to treatment with either busulfan 16 mg/kg (n = 88) or total body irradiation ([TBI] n = 79) in addition to cyclophosphamide 120 mg/kg. The patients were observed for a period of 5 to 9 years. Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =.01) and hemorrhagic cystitis (32% v 10%, P =.003). Acute graft-versus-host disease (GVHD) was similar in the two groups, but the 7-year cumulative incidence of chronic GVHD was 59% in the busulfan-treated group versus 47% in the TBI group (P =.05). Death from GVHD was more common in the busulfan group (22% v 3%, P <.001). Obstructive bronchiolitis occurred in 26% of the busulfan patients but in only 5% of the TBI patients (P <.01). Complete alopecia developed in 8 busulfan patients and partial alopecia in 17, versus five with partial alopecia in the TBI group (P <.001). Cataracts occurred in 5 busulfan-treated patients and 16 TBI patients (P =.02). The incidence of relapse after 7 years was 29% in both groups. Seven-year transplant-related mortality (TRM) in patients with early disease was 21% in the busulfan group and 12% in the TBI group. In patients with more advanced disease, the corresponding figures were 64% and 22%, respectively (P =.004). Leukemia-free survival (LFS) in patients with early disease was 68% in busulfan-treated patients and 66% in TBI patients. However, 7-year LFS in patients with more advanced disease was 17% in the busulfan group versus 49% in the TBI group (P <.01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively. (+info)Busulphan level and early mortality in thalassaemia patients after BMT. (7/594)
The aim of the study was to correlate busulphan (BU) levels of thalassaemia patients with outcome of allogeneic transplant. BU levels were measured by gas chromatography mass fragmentography. All patients received a standardised dose of BU 16 mg/kg, and cyclophosphamide 150 or 200 mg/kg. For area-under-the-curve analysis (AUC), blood samples were obtained at 0, 1, 2, 3, 4 and 6 h after the first and fifth dose for all patients, and additional levels were measured after ninth and/or 13th dose in most patients. Outcome parameters examined included veno-occlusive disease of liver (VOD), idiopathic interstitial pneumonitis, chimerism, and day 90 survival. Twenty consecutive thalassaemia patients who underwent haematopoietic stem cell transplantation were studied. The median age at transplant was 11.2 years (range 3-21 years). Mean BU AUC levels were correlated with age at transplant (r = 0.58, P = 0.007). Nine patients developed VOD and six had mixed chimerism, but these did not correlate with mean BU AUC level. Four patients died before day 50 from VOD and interstitial pneumonitis. Patients with BU AUC levels greater than the median (908 micromol x min/l) had significantly lower probability of survival at day 90 (60%), whereas patients with BU AUC level less than the median all survived beyond day 90. No patient had graft rejection. In conclusion, a high BU AUC level was associated with a higher treatment-related mortality in thalassaemia patients after transplant. (+info)Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. (8/594)
Treatment of choroidal melanoma by chemotherapy is usually unsuccessful, with response rates of less than 1% reported for dacarbazine (DTIC)-containing regimens which show 20% or more response rates in skin melanoma. Recently, we reported the activity of several cytotoxic agents against primary choroidal melanoma in an ATP-based tumour chemosensitivity assay (ATP-TCA). In this study, we have used the same method to examine the sensitivity of choroidal melanoma to combinations suggested by our earlier study. Tumour material from 36 enucleated eyes was tested against a battery of single agents and combinations which showed some activity in the previous study. The combination of treosulfan with gemcitabine or cytosine arabinoside showed consistent activity in 70% and 86% of cases, respectively. Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%). Addition of paclitaxel to the combination of treosulfan + cytosine analogue added little increased sensitivity. For treosulfan + cytosine arabinoside, further sequence and timing experiments showed that simultaneous administration gave the greatest suppression, with minor loss of inhibition if the cytosine analogue was given 24 h after the treosulfan. Administration of cytosine analogue 24 h before treosulfan produced considerably less inhibition at any concentration. While we have so far been unable to study metastatic tumour from choroidal melanoma patients, the combination of treosulfan with gemcitabine or cytosine arabinoside shows activity ex vivo against primary tumour tissue. Clinical trials are in progress. (+info)
Busulfan - Wikipedia
Therapeutic Drug Monitoring Can Improve Target Exposure Levels of Busulfan Prior to Allogenic Hematopoietic Cell...
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation...
Busulfan and Fludarabine in Patients With AML and MDS - Full Text View - ClinicalTrials.gov
Busulfan induced azoospermia: Stereological evaluation of testes in rat
Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous...
Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and...
Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen | Clinical Research...
Which Dose of Busulfan Is Best | AACC.org
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI) | Aplastic Anemia and MDS...
BUSULFAN- busulfan injection | myHealthbox
Busulfan - Biology-Online Dictionary
busulfan | Definition of busulfan in English by Oxford Dictionaries
Busulfan IC50 - Drug Resistance to EGFR Inhibitors in Lung Cancer
Busulfan | CancerQuest
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD...
Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release...
Plus it
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Precision Dosing and Therapeutic Drug Monitoring for Busulfan and Vancomycin
busulfan | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice | Protocol (Translated to...
Chemo Day 5 - Life Of Riley Jane
DMOZ - Health: Pharmacy: Drugs and Medications: B: Busulfan
Busulfan - Antineoplastic agents - Pocket Drug Guide
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Rada Savic, PhD | School of Pharmacy | UCSF
Free The Scandal Of Scientology 1971
Q78-95: Laboratory Findings Prior to the Start of the Preparative Regimen / Infusion
Strengths Available for Busulphan | SaveRxCanada.to
Busulfan (Intravenous Route) Description and Brand Names - Mayo Clinic
MedlinePlus - Search Results for: Busulfan
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long...
FLAGYL 375 - Infectious Disease Advisor
DDrare: Database of Drug Development for Rare Diseases
Inefficient clearance of myelin debris by microglia impairs remyelinating processes | JEM
Purpose In multiple cell metazoans, the ability of polarized epithelial cells - Drug Resistance to EGFR Inhibitors in Lung...
Ash Stevens Inc. to Present Development of Highly Potent Anti-Cancer Drug Busulfan at AACR Annual Meeting
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety...
The Protective Effects of Melatonin on the Histological Changes of Testis in Busulfan-Treated Adult Mice
Stem Cells | Childrens Dayton
Jason Law, MD | Tufts Medical Center
May 2015 | ALS Support and Help Forum
Myleran Side Effects in Detail - Drugs.com
Outcome of haploidentical hematopoietic stem cell transplantation for refractory/relapsed acute leukemia] | Read by QxMD
Busulfan Drug Interactions - Drugs.com
ATG vs. thiotepa with Busulfan and Cyclophosphamide in matched-related bone marrow transplantation for thalassemia |...
February 2018 - BUSULFAN generic equivalents, drug patent expiration information and freedom to operate
ChemoGLO - Chemotherapy Wipe Studies
ChemoGLO - Chemotherapy Wipe Studies
JCI -
Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses
KLUVER BUCY SYNDROME PDF
Likumi.lv - Latvijas Republikas tiesību akti
Search
Kichik waqitlirimizdiki naxshilar
Alkyl sulfonate
Busulfan. Römpp CD 2006, Georg Thieme Verlag 2006 v t e. ...
Ethane dimethanesulfonate
Busulfan Risbridger, GP; Davies, A (June 1994). "Isolation of rat Leydig cells and precursor forms after administration of ...
Chemotherapy
2014). "Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem ... Carboplatin and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each person. Simple blood ... Chemotherapies with high risk include procarbazine and other alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ...
Mannosulfan
Research suggests it is less toxic than the alkyl sulfonate Busulfan. Jeswani G, Paul SD (2017). "Recent Advances in the ...
California Institute for Regenerative Medicine
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. In 2017, CIRM awarded $2 million to a ... "Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1". New England Journal of Medicine. 380 (16): ...
Bcr-Abl tyrosine-kinase inhibitor
Only cytotoxic drugs such as busulfan, hydroxyurea or interferon-alpha (rIFN-α) were utilized. Even though the first Bcr-Abl TK ...
Zdravila z delovanjem na novotvorbe - Wikipedija, prosta enciklopedija
Sem spadajo analogi dušikovega iperita (melfalan, klorambucil ...), alkilsulfonati (busulfan ...), epoksidi ... Zaviralci ...
Chemotherapy
"Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell ... Carboplatin[25]:4 and busulfan[26][27] dosing rely upon results from blood tests to calculate the optimal dose for each patient ... Most chemotherapy is delivered intravenously, although a number of agents can be administered orally (e.g., melphalan, busulfan ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ...
PAX7
Additionally, mice lacking PAX7 had delayed recovery of spermatogenesis following exposure to busulfan when compared to control ...
Fertility preservation
Chemotherapies with high risk include procarbazine and alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, ...
Dimethylacetamide
... is also used as an excipient in drugs, e.g. in Vumon (teniposide), Busulfex (busulfan) or Amsidine (amsacrine ...
Ectrodactyly
Naruse, Takuji; Takahara, Masatoshi; Takagi, Michiaki; Oberg, Kerby C.; Ogino, Toshihiko (2007). "Busulfan-induced central ...
Total body irradiation
1996). "Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone ...
Hematopoietic stem cell transplantation
January 2012). "Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in ...
Female infertility
... busulfan, melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as ...
Chemotherapy-induced hyperpigmentation
... cyclophosphamide and busulfan). Skin lesion James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin ...
Spermatogonial stem cell
took out and isolated SSCs from prepubertal and adult rhesus macaques before treating them with busulfan (an alkylating agent ...
Hematopoietic stem cell transplantation
... busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma". Biol Blood Marrow ...
Delcath Systems
... busulfan, capecitabine). University of Pittsburgh Medical Center National Cancer Institute in Bethesda, Maryland Albany Medical ...
Specialty drugs in the United States
... busulfan, capecitabine). Delcath Systems, Inc. (NASDAQ: DCTH) a specialty pharmaceutical and medical device company ...
Treosulfan
Two main studies showed that treosulfan is at least as effective as busulfan, another medicine used to prepare patients for ... of patients given busulfan (with fludarabine). In an additional study in 70 children with blood cancers, 99% of children given ...
Pulmonary fibrosis
Infections Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, methotrexate, apomorphine, and ...
Myelodysplastic syndrome
... busulfan, and chlorambucil) or radiation (therapeutic or accidental), or both (e.g., at the time of stem cell transplantation ... MDS after exposure to radiation or alkylating agents such as busulfan, nitrosourea, or procarbazine, typically occurs 3-7 years ...
Teva Pharmaceuticals
Aviane Azathioprine Azithromycin Baclofen Balziva Bisoprolol Fumarate Bleomycin Budeprion Budesonide Buspirone Busulfan ...
Strimvelis
... the person is treated with busulfan or melphalan to kill as many of the person's existing HSCs to increase the chances of the ...
Pulmonary toxicity
... busulfan, cyclophosphamide, chlorambucil, and nitrosourea (e.g., carmustine). Also, some medicinal drugs used in cardiovascular ...
ATC code L01
L01AA05 Chlormethine L01AA06 Ifosfamide L01AA07 Trofosfamide L01AA08 Prednimustine L01AA09 Bendamustine L01AB01 Busulfan ...
FLAG (chemotherapy)
In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan ...
George W. Santos
... contributions was the development of the regimen to prepare patients for the procedure by using the anticancer drugs busulfan ...
Busulfan: MedlinePlus Drug Information
Busulfan: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking busulfan,. *tell your doctor and pharmacist if you are allergic to busulfan, any other medications, or any of the ... Busulfan may increase the risk that you will develop other cancers. Talk to your doctor about the risks of taking busulfan. ... If you become pregnant while taking busulfan, call your doctor immediately. Busulfan may harm the fetus. ...
Busulfan - Wikipedia
Concomitant use of acetaminophen within 72 hours of busulfan use can reduce busulfan clearance (resulting in increased busulfan ... Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). However, clinical studies of busulfan ... Oral bioavailability of busulfan shows a large interindividual variation. Taking busulfan on an empty stomach is recommended to ... Fludarabine + busulfan is a typical example of this use. Toxicity may include interstitial pulmonary fibrosis ("busulfan lung ...
Busulfan - National Cancer Institute
This page contains brief information about busulfan and a collection of links to more information about the use of this drug, ... MedlinePlus Information on Busulfan (Myleran) and Busulfan (Bulsulfex) - Lay language summaries of important information about ... Busulfan is approved to treat:. *Chronic myelogenous leukemia (CML). *It is used as palliative treatment. This use is approved ... More About Busulfan. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. ...
Busulfex (busulfan) for Leukemia: Side Effects & Warnings
... busulfan) is a cancer medication used to treat chronic myelogenous leukemia (a type of blood cancer). Busulfex is not a cure ... Generic drug: busulfan. Brand name: Busulfex. What is Busulfex (busulfan), and how does it work?. Busulfex (busulfan) is a ... Itraconazole decreases busulfan clearance by up to 25%. Metronidazole decreases the clearance of busulfan to a greater extent ... Busulfex (bus ulfan) Injection causes severe and prolonged myelosuppression at the recommended dos age. Hematopoietic ...
Busulfan Drug Interactions - Drugs.com
306 medications are known to interact with busulfan. Includes Acidophilus (lactobacillus acidophilus), AmBisome (amphotericin b ... Show all medications in the database that may interact with busulfan.. Check for interactions with busulfan. Type in a drug ... A total of 306 drugs (1693 brand and generic names) are known to interact with busulfan. ... Common medications checked in combination with busulfan. *Acidophilus (lactobacillus acidophilus). *AmBisome (amphotericin b ...
DailyMed - BUSULFAN injection
BUSULFAN (UNII: G1LN9045DK) (BUSULFAN - UNII:G1LN9045DK) BUSULFAN. 6 mg in 1 mL. ... Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or ... 6.3 Oral Busulfan Literature Review 7 DRUG INTERACTIONS 7.1 Drugs that Decrease Busulfan Injection Clearance 7.2 Drugs that ... The molecular formula of busulfan is CH 3SO 2O(CH 2) 4OSO 2CH 3 and a molecular weight of 246 g/mole. Busulfan has the ...
Busulfan - definition of busulfan by The Free Dictionary
busulfan synonyms, busulfan pronunciation, busulfan translation, English dictionary definition of busulfan. n. An alkylating ... Busulfan - definition of busulfan by The Free Dictionary https://www.thefreedictionary.com/busulfan ... busulfan. Also found in: Medical, Financial, Encyclopedia, Wikipedia. bu·sul·fan. (byo͞o-sŭl′fən). n.. An alkylating agent, C6H ... busulfan. n busulfán m, busulfano (INN). English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill ...
Treosulfan Better Than Busulfan in Prep for HSCT
... rather than busulfan-based regimen, German scientists have shown. ... Treosulfan Better Than Busulfan in Prep for HSCT. Liam ... Patients given treosulfan were more likely to have AML (70.5%) than MDS (29.5%), but the spread was more even in the busulfan ... The results showed that not only was a treosulfan-based regimen noninferior to one containing busulfan in terms of event-free ... HOUSTON - Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable ...
Busulfan | Memorial Sloan Kettering Cancer Center
DailyMed - BUSULFAN injection, solution
BUSULFAN (UNII: G1LN9045DK) (BUSULFAN - UNII:G1LN9045DK) BUSULFAN. 6 mg in 1 mL. ... Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or ... 6.3 Oral Busulfan Literature Review 7 DRUG INTERACTIONS 7.1 Drugs that Decrease Busulfan Injection Clearance 7.2 Drugs that ... Busulfan is dissolved in DMA, 3.3 mL and Polyethylene Glycol 400, NF 6.7 mL. The solubility of busulfan in water is 0.1 g per L ...
Busulfan - Wikipedia
Concomitant use of acetaminophen within 72 hours of busulfan use can reduce busulfan clearance (resulting in increased busulfan ... Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). However, clinical studies of busulfan ... Oral bioavailability of busulfan shows a large interindividual variation.[6] Taking busulfan on an empty stomach is recommended ... Busulfan is metabolized via glutathione conjugation in the liver to inactive metabolites. Itraconazole can decrease busulfan ...
Busulfan facts, information, pictures | Encyclopedia.com articles about Busulfan
Make research projects and school reports about Busulfan easy with credible articles from our FREE, online encyclopedia and ... Busulfan Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Busulfan. Definition. Busulfan (also known by the ... Busulfan, when used for bone marrow transplants, is dosed by patient body weight. Busulfan is usually given at a dose of 4mg ... Busulfan is taken orally and comes in tablet form.. Recommended dosage. Busulfan can be taken following several different ...
Busulfan - Medical Dictionary / Glossary | Medindia
Busulfan - An anticancer drug that belongs to the family of drugs called alkylating agents, is clearly explained in Medindia s ... Busulfan - Glossary. Written & Compiled by Medindia Content Team. Medically Reviewed by The Medindia Medical Review Team on May ... Medical Word - Busulfan. Ans : An anticancer drug that belongs to the family of drugs called alkylating agents. ...
Busulfan dictionary definition | busulfan defined
... that is used as an antineoplastic drug in the treatment of chronic myelogenous leukemia.Origin of busulfan bu(tane) alteration ... busulfan. bu·sul·fan. noun. An alkylating agent, C6H14O6S2, that is used as an antineoplastic drug in the treatment of chronic ... Busulfan. (n.d.). In YourDictionary. Retrieved from https://www.yourdictionary.com/Busulfan ... Busulfan. (n.d.). In YourDictionary. Retrieved from https://www.yourdictionary.com/Busulfan ...
Busulfex (Busulfan): Side Effects, Interactions, Warning, Dosage & Uses
Busulfan) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related ... The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in ... Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%).. Metabolism: Busulfan is predominantly metabolized ... Oral Busulfan Literature Review: Four publications of randomized, controlled trials that evaluated a high-dose oral busulfan- ...
Busulfan (oral/injection) Uses, Side Effects & Warnings - Drugs.com
... includes busulfan (oral/injection) description, dosage and directions. ... Physician reviewed busulfan (oral/injection) (oral/injection) patient information - ... Busulfan (oral/injection). Generic Name: busulfan (oral/injection) (bue SUL fan). Brand Name: Busulfan, Busulfex, Myleran ... Take the busulfan oral tablet with a full glass of water.. Busulfan injection is given as an infusion into a vein in your upper ...
Busulfan (Intravenous Route) Description and Brand Names - Mayo Clinic
Busulfan belongs to the group of medicines known as alkylating agents. It seems to act by interfering with the function of the ... Since the growth of normal body cells may also be affected by busulfan, other effects will also occur. Some of these may be ... Before you begin treatment with busulfan, you and your doctor should talk about the benefits this medicine will do as well as ... Busulfan injection is used in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic ...
Busulfan (Intravenous Route) Description and Brand Names - Mayo Clinic
Information about this busulfan-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Thalassemia-Busulfan may cause increased pressure within the heart in children. Proper Use. A nurse or other trained health ... Busulfan must be given slowly, so the needle will remain in place for 2 hours. You may also receive medicines to help prevent ... Busulfan belongs to the group of medicines known as alkylating agents. It seems to act by interfering with the function of the ...
Busulfan | CancerQuest
Busulfan is used to treat chronic myelogenous leukemia. Busulfan is usually administered as an oral tablet. 12 ... Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may ... Busulfan (Myleran®) is an alkylating agent that prevents DNA synthesis and transcription and induces (causes) nucleotide ... The most common adverse effect of busulfan is bone marrow depression which results in altered blood cell counts. For this ...
MedlinePlus - Search Results for: Busulfan
Busulfan Busulfan is used treat a certain type of chronic myelogenous leukemia (CML; a type of cancer of the white blood cells ... Busulfan Injection Busulfan injection is used to treat a certain type of chronic myelogenous leukemia (CML; a type of ... cells ... Cancers of the lung, breast, and ovary Examples: Busulfan (Myleran) Cyclophosphamide Temozolomide (Temodar) Caution: May damage ... Chemotherapy and hormonal medicines: Antiandrogens (Casodex, Flutamide, Nilutamide) Busulfan (Myleran) Cyclophosphamide ( ...
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation - Full Text View - ClinicalTrials.gov
Drug: Busulfan Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation ... Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation. The safety and scientific validity of this study is the ... Drug Information available for: Busulfan Clofarabine Genetic and Rare Diseases Information Center resources: Myelodysplastic ... In this research study, the investigators are looking to see how well this new combination of busulfan and clofarabine works in ...
Myleran Tablets (Busulfan Tablets) Side effects, Images, Uses, Dosage, Overdose at RxList
Busulfan Tablets)? Learn about drug imprint, side effects, uses (treating), dosage, interaction, overdose, and warnings. ... What is busulfan (Busulfan, Busulfex, Myleran)?. *What are the possible side effects of busulfan (Busulfan, Busulfex, Myleran)? ... What should I avoid while using busulfan (Busulfan, Busulfex, Myleran)?. *What other drugs will affect busulfan (Busulfan, ... What is busulfan (Busulfan, Busulfex, Myleran)?. Busulfan oral (taken by mouth) is used to treat the symptoms of chronic ...
Which Dose of Busulfan Is Best | AACC.org
The target area under the plasma concentration vs time curve (AUC) for busulfan was set at 950 μmol · L−1 · min−1, near the low ... The patient received 2-hour intravenous infusions of busulfan every 6 h for 4 days (16 doses total). The patient was ... A 24-year-old woman with advanced Hodgkin disease received the standard dosing protocol for busulfan/cyclophosphamide before ... Can the coadministration of multiple drugs during busulfan therapy affect the PK of busulfan? ...
Busulfan (injection) - wikidoc
djusting busulfan dosage based on gender has not been adequately studied. Race. djusting busulfan dosage based on race has not ... Busulfan is a presumed human carcinogen. Clinical Studies. Documentation of the safety and efficacy of busulfan as a component ... In the busulfan allogeneic stem cell transplantation clinical trial, all patients were treated with busulfan 0.8 mg/kg as a two ... Busulfan has not been studied in patients with renal impairment. Hepatic Impairment. Busulfan has not been administered to ...
Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. - PubMed - NCBI
... after the first dose of busulfan was measured in patients receiving a 16-dose course of busulfan as part of a BMT preparative ... Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.. Grochow LB1. ... High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. The dose-limiting ... In 27 patients who showed high AUCs (, 1,500 mumol.min/L) after the first dose, the fifth through 16th doses of busulfan were ...
Ash Stevens Inc. to Present Development of Highly Potent Anti-Cancer Drug Busulfan at AACR Annual Meeting
ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic ... will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic ... Ammoscato will present on the handling and manufacture of the highly potent busulfan active pharmaceutical ingredient (API) as ... to Present Development of Highly Potent Anti-Cancer Drug Busulfan at AACR Annual Meeting ...
Busulfan injection - AHealthyMe - Blue Cross Blue Shield of Massachusetts
Busulfan - Biology-Online Dictionary
Busulfan (Science: chemical) An alkylating agent having a selective immunosuppressive effect on bone marrow. It has been used ... According to the fourth annual report on carcinogens (ntp 85-002, 1985), busulfan is listed as a known carcinogen. ... Busulfan. Revision as of 21:16, 3 October 2005 by WikiConvertor (Talk) ... Retrieved from "http://www.biology-online.org/bodict/index.php?title=Busulfan&oldid=18914" ...
Busulfan and Fludarabine in Patients With AML and MDS - Full Text View - ClinicalTrials.gov
Experimental: Busulfan + Fludarabine Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours ... Busulfan and Fludarabine in Patients With AML and MDS. The safety and scientific validity of this study is the responsibility ... Drug: Busulfan 130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting ... High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately ...
IJMS | Free Full-Text | Gosha-Jinki-Gan Recovers Spermatogenesis in Mice with Busulfan-Induced Aspermatogenesis
After busulfan treatment, the weight of the testes and the epididymal sperm count progressively decreased in the normal diet ... Male 4-week-old C57BL/6J mice were administered a single intraperitoneal injection of busulfan, and they were then fed a normal ... These results suggest that busulfan-induced aspermatogenesis is irreversible if appropriate treatment is not administered. ... to mice suffering from severe aspermatogenesis after busulfan treatment to determine whether TJ107 can recover spermatogenesis ...
MyleranBusulfexCyclophosphamideDoseIntravenous BusulfanInjectionTotal body irradiDoses of busulfanRegimenSide effects of busulfanPatientsTransplantationTherapeuticPharmacokineticsMyeloablativeSeizuresStop taking bToxicity of busulfanDrugsMedicationTake busulfanQuantification of Busulfan in plasmaRegimensCONTRAINDICATIONSBoneOralConcentrationChronic myelogenAllergic reaction to busulfanSevere aspermatogenesis after busulfanChemotherapeuticByoo SUL fanTreatmentDrugGlutathionePhenytoinIrradiationExposure to busulfanClearance of busulfanTherapy with busulfanInteract with busulfanFludarabine and busulfanMedicinesPregnantStemMiceIntravenouslyTabletsTaken busulfanStandard busulfan
Myleran10
- This use is approved for the Myleran brand of busulfan. (cancer.gov)
- MedlinePlus Information on Busulfan (Myleran) and Busulfan (Bulsulfex) - Lay language summaries of important information about these drugs. (cancer.gov)
- Myleran is supplied in white film coated tablets with 2 mg of busulfan per tablet. (wikipedia.org)
- Busulfan (also known by the brand name Myleran) is a chemotherapy medicine used to treat cancer by destroying cancerous cells. (encyclopedia.com)
- What are the possible side effects of busulfan (Busulfan, Busulfex, Myleran)? (rxlist.com)
- What is the most important information I should know about busulfan (Busulfan, Busulfex, Myleran)? (rxlist.com)
- What should I discuss with my healthcare provider before using busulfan (Busulfan, Busulfex, Myleran)? (rxlist.com)
- Myleran (Busulfan) is a chemotherapy medication used in the treatment of some types of leukemia . (healthtap.com)
- When taken as directed, the active ingredient in Myleran, called Busulfan, will work to interfere with the DNA so the cancer cells cannot 'read' their codes in order to be able to copy the DNA and create even more cancer cells. (discountdrugsfromcanada.com)
- Busulfan tablets (Myleran) for leukaemia. (high-kick.ru)
Busulfex13
- This use is approved for the Busulfex brand of busulfan. (cancer.gov)
- Busulfex is supplied as an intravenous solution with 6 mg/ml busulfan. (wikipedia.org)
- Busulfex has proved equally effective as oral busulfan, with presumedly less toxic side effects. (wikipedia.org)
- What is Busulfex (busulfan), and how does it work? (medicinenet.com)
- Busulfex ( busulfan ) is a cancer ( antineoplastic ) medication used to treat the symptoms of chronic myelogenous leukemia (a type of blood cancer ). (medicinenet.com)
- Discontinue iron chelating agents well in advance of administration of Busulfex to avoid increased exposure to busulfan. (medicinenet.com)
- Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to (less than 72 hours) or concurrent with Busulfex may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues. (medicinenet.com)
- BUSULFEX ® (busulfan) Injection is intended for intravenous administration. (rxlist.com)
- Each vial of BUSULFEX contains 60 mg (6 mg/mL) of busulfan, the active ingredient, a white crystalline powder with a molecular formula of CH 3 SO 2 O(CH 2 ) 4 OSO 2 CH 3 and a molecular weight of 246 g/mole. (rxlist.com)
- The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP as recommended for infusion reflects the pH of the diluent used and ranges from 3.4 to 3.9. (rxlist.com)
- The diluent quantity should be 10 times the volume of BUSULFEX, so that the final concentration of busulfan is approximately 0.5 mg per mL. (rxlist.com)
- Captisol Enabled™ Busulfan is designed to remove the toxic excipients N,N-dimethylacetamide (DMA) and polyethylene glycol (PEG), which are present in the marketed product IV BUSULFEX® (busulfan). (ligand.com)
- rATG on days -3, -2 and -1 Other Names: Fludara Busulfex Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI) Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant. (aamds.org)
Cyclophosphamide19
- Busulfan is used in pediatrics and adults in combination with cyclophosphamide or fludarabine/clofarabine as a conditioning agent prior to bone marrow transplantation, especially in chronic myelogenous leukemia (CML) and other leukemias, lymphomas, and myeloproliferative disorders. (wikipedia.org)
- As an adjunct therapy with cyclophosphamide for conditioning prior to bone marrow transplantation in adults and children >12 kg, intravenous (IV) busulfan (Bulsulfex) is dosed at 0.8 mg/kg every six hours for 16 doses (four days). (wikipedia.org)
- Cardiac tamponade has been reported in pediatric patients with thalassemia who received high doses of oral busulfan and cyclophosphamide. (nih.gov)
- Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. (nih.gov)
- Administer Busulfan Injection in combination with cyclophosphamide as a conditioning regimen prior to bone marrow or peripheral blood progenitor cell replacement. (nih.gov)
- cyclophosphamide, busulfan , and/or radiation(XRT)), development of acute GVHD, and CMV reactivation were also considered risk factors for the development of HC. (thefreedictionary.com)
- We concluded that previous chemotherapy with multiple agents, including high dose busulfan and cyclophosphamide for stem cell transplant conditioning had led to premature ovarian failure causing her severe climacteric problems. (thefreedictionary.com)
- Busulfan injection is used together with a medicine called cyclophosphamide , to prepare your body to receive a stem cell transplant from a donor's bone marrow. (drugs.com)
- A 24-year-old woman with advanced Hodgkin disease received the standard dosing protocol for busulfan/cyclophosphamide before allogeneic hematopoietic stem cell transplantation (HSCT)1 from a matched unrelated donor. (aacc.org)
- Busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation. (healthdirect.gov.au)
- HRD recipients received low-dose cyclophosphamide for 2 days, fludarabine for 5 days, 2 to 3 days of busulfan depending on cytogenetics, and 200 cGy total body irradiation. (unboundmedicine.com)
- In a previous phase I study, it was concluded that tolerable doses of busulfan (BU), cyclophosphamide (CY) and total body irradiation (TBI) were 8 mg/kg, 60 mg/kg and 12.0 Gy, respectively, for autologous marrow transplant recipients. (nih.gov)
- Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide. (thefreedictionary.com)
- 3) These include the antiarrhythmic drug amiodarone, the chemotherapeutic agents bleomycin, busulfan , carmustine and cyclophosphamide, the immunosuppressive drugs sirolimus and everolimus and many others. (thefreedictionary.com)
- Others (cyclophosphamide, busulfan , and carmustine) can cause it even years after completion of therapy. (thefreedictionary.com)
- busulfan , melphalan, cyclophosphamide) doxorubicin, daunorubicin cause stomatitis and patients with hematological malignancies are more prone to the occurrence of oral complications [7]. (thefreedictionary.com)
- Busulfan at high doses (usually 16 mg/kg) given with other cytotoxic drugs (especially cyclophosphamide) is a common preparative regimen in patients undergoing allogeneic or autologous bone marrow transplantation (BMT) for acute or chronic leukemia and other nonmalignant disorders (e.g., hemoglobinopathies, inborn error of immune system, congenital metabolic disorders). (elsevier.com)
- A reduced incidence of hepatic VOD has been seen in those patients given high-dose busulfan and cyclophosphamide when the first dose of cyclophosphamide has been delayed for more than 24 hours after the last dose of busulfan. (pocketdrugguide.com)
- The goal of this clinical research study is to learn if busulfan with cyclophosphamide (when given with other helper drugs listed below) can help control the diseases listed above when given before a stem cell transplant. (sparkcures.com)
Dose61
- Your doctor may need to change your dose or tell you to stop taking busulfan for a period of time to allow your blood count to return to normal if it has dropped too low. (medlineplus.gov)
- Your doctor may adjust your dose of busulfan depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
- Both IV and oral formulations require prophylactic antiemetic agents administered prior to the busulfan dose and scheduled antiemetics administered thereafter. (wikipedia.org)
- Busulfan therapeutic drug monitoring is completed based on trough (pre-dose) levels with a target six-hour area under the curve (AUC) of between 900 and 1500 micromolxmin. (wikipedia.org)
- However, clinical studies of busulfan were completed with patients taking phenytoin, so no empiric dose adjustment is necessary if patients are taking phenytoin with busulfan. (wikipedia.org)
- Finally, the stem cells are infused back into the patient, who has received a low dose of the chemotherapy medication busulfan to help the genetically corrected stem cells establish themselves in the bone marrow and begin producing new blood cells. (thefreedictionary.com)
- Busulfan is a 2mg oral tablet, and patients may need to take more than one tablet at a time depending on the dose. (encyclopedia.com)
- The dose of busulfan for use in combination with other chemotherapy drugs before a bone marrow transplant is much larger than leukemia dosing. (encyclopedia.com)
- In bone marrow transplant patients, the dose of busulfan that is given in combination with other chemotherapy drugs is intended to cause complete bone marrow destruction prior to bone marrow transplant. (encyclopedia.com)
- High-dose busulfan may affect fertility (ability to have children) in women, either temporarily or permanently. (drugs.com)
- Since busulfan injection is given by a healthcare professional, you are not likely to miss a dose. (drugs.com)
- According to these results, the predicted busulfan dosage required to achieve the target AUC was 75 mg per dose for the remaining 14 scheduled doses. (aacc.org)
- Because of the large change in dosage, additional PK monitoring of busulfan was performed after the fifth dose (day 2). (aacc.org)
- The fifth dose was selected to allow time to reach a steady-state concentration (Css) after the dosage adjustment and to avoid challenges in interpretation due to possible circadian variation in busulfan concentrations (1). (aacc.org)
- Additional monitoring of busulfan was performed immediately after the ninth dose because of another change in dose and potential reduced clearance through busulfan interaction with fluconazole. (aacc.org)
- The busulfan dose was decreased to 39 mg for the remaining doses because the AUC was near the high end of the therapeutic range and because clearance was reduced between the fifth and ninth doses. (aacc.org)
- The most frequent serious consequence of treatment with busulfan at the recommended dose and schedule is profound myelosuppression , occurring in all patients. (wikidoc.org)
- Seizures have been reported in patients receiving high-dose oral busulfan at doses producing plasma drug levels similar to those achieved following the recommended dosage of busulfan. (wikidoc.org)
- High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. (nih.gov)
- The dose-limiting toxicity of busulfan in BMT regimens is hepatic veno-occlusive disease (VOD), which occurs in approximately 20% to 40% of patients. (nih.gov)
- The area under the curve of time versus concentration (AUC) after the first dose of busulfan was measured in patients receiving a 16-dose course of busulfan as part of a BMT preparative regimen. (nih.gov)
- 1,500 mumol.min/L) after the first dose, the fifth through 16th doses of busulfan were decreased. (nih.gov)
- To administer multiple doses of an intravenous formulation of busulfan (Bu) at a dose adjusted to yield a blood drug level with a median daily area under the plasma concentration curve (AUC) of approximately 6,500 µMol-min. (clinicaltrials.gov)
- this information will be used to determine the subsequent high-dose busulfan doses. (clinicaltrials.gov)
- Patients who do not agree to the optional pharmacology procedure will receive a fixed dose of busulfan as has previously been done for 3 years. (clinicaltrials.gov)
- High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately after fludarabine. (clinicaltrials.gov)
- Between Days -15 and -8, you will receive a low-level "test" dose of busulfan by vein over about 45 minutes to 1 hour. (knowcancer.com)
- Test doses are used to study how your body breaks down busulfan and decide the dose of busulfan that you will receive. (knowcancer.com)
- Blood (about 1 teaspoon each time) will then be drawn for PK testing up to 11 times over the 11 hours after the busulfan test dose. (knowcancer.com)
- If for any reason it is not possible for the PK tests to be performed, you will receive the standard dose of busulfan. (knowcancer.com)
- On Days -6 through -3, you will receive clofarabine by vein over 1 hour, followed by your dose of busulfan by vein over 3 hours. (knowcancer.com)
- If for any reason you could not have the PK tests performed, you will receive the standard busulfan dose on these days. (knowcancer.com)
- Cohorts of 3-6 patients receive escalating doses of busulfan until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
- Busulfan, at a dose of 2 mg/day, is an effective option for elderly patients with PV or ET who fail to hydroxyurea, but a significant rate of transformation was observed. (sigmaaldrich.com)
- The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. (clinicaltrials.gov)
- Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. (clinicaltrials.gov)
- To assess safety and toxicity of the addition of busulfan added to an established fludarabine and low-dose total-body irradiation (TBI) conditioning regimen for non-myeloablative allogeneic transplantation in patients with hematologic malignancies. (clinicaltrials.gov)
- Since the polymorphic mu-class GST catalyzed busulfan conjugation, we examined busulfan clearance in 50 patients undergoing high-dose busulfan before bone marrow transplantation. (aspetjournals.org)
- This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation. (aamds.org)
- Subjects will be randomly assigned to receive one of 2 conditioning regimen: fludarabine and busulfan, or fludarabine busulfan and low dose total body irradiation (TBI). (aamds.org)
- Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose) Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant. (aamds.org)
- It is the consensus of the eviQ BMT Reference Committee not to divide the dose of busulfan as per Rambaldi 2015. (eviq.org.au)
- Therapeutic drug monitoring (TDM) of Busulfan is essential for management of Bone Marrow Transplant (BMT) patients, by optimizing dose, supporting compliance, and minimizing toxicity. (labroots.com)
- Objective: To examine the effi cacy and safety of hematopoietic stem cell transplantation (HSCT) after low-dose (50-65 %) Busulfan, full-dose Fludarabine conditioning and in-vivo T-cell depletion in high-risk pediatric and adult chronic granulomatous disease (CGD) patients. (aspergillus.org.uk)
- Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of hematopoietic stem cell transplantation (HSCT). (uu.nl)
- For the 12 months ending 30 September 2017, the US sales for Busulfan Injection, 60 mg/10 ml (6 mg/ml) single-dose vial were approximately USD97m, according to IQVIA. (thefreedictionary.com)
- Oral lorazepam prevents seizure during high-dose busulfan in c. (mysciencework.com)
- Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. (mysciencework.com)
- High-dose Busulfan in combination chemotherapy has been used commonly for hematopoietic stem cell transplantation. (mysciencework.com)
- None of the patients developed seizure while receiving oral lorazepam or within 72 hours of the last dose of Busulfan. (mysciencework.com)
- In the authors' experience, oral lorazepam is a useful anticonvulsant prophylaxis for children receiving high-dose busulfan. (mysciencework.com)
- Busulfan Injection is packaged as a sterile solution in 10 mL single-dose clear glass vials each containing 60 mg of busulfan at a concentration of 6 mg per mL for intravenous use, NDC 16729-351-03. (myhealthbox.eu)
- Pharmacokinetics of high-dose busulfan are age-dependent. (elsevier.com)
- High-dose busulfan used in conditioning regimens for haematopoietic stem cell transplantation may increase the risk of lateonset haemorrhagic cystitis. (pocketdrugguide.com)
- Dose-dependent veno-occlusive disease (VOD) has been reported in 20 to 40% of patients receiving high-dose busulfan before bone marrow transplantation. (pocketdrugguide.com)
- High-dose busulfan, used in conditioning regimens for bone marrow transplantation, has been associated with the development of convulsions, both generalised and myoclonic. (pocketdrugguide.com)
- The first group was injected by single dose of busulfan (10 mg kg -1 ) and their testes were removed on day 35 post injection. (iranjournals.ir)
- Busulfan, 1,4-bis [methanesulfonyl-y] butane, is a chemotherapeutic agent that most often is used as low dose in a long time manner to treat chronic myeloid leukaemia. (iranjournals.ir)
- 10 The number of reports about busulfan side effects on testicular architecture and fertility indices in animal model are scarce, therefore, the aims of this study were to evaluate the stereological changes of testicular tissue in response to single and two dose of busulfan injection in male rat and comparing them together and with normal control. (iranjournals.ir)
- a,b) Messenger RNA from the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) was assayed by quantitative RT-PCR and normalized to control, showing that all were upregulated after busulfan treatment in U2OS (a) and MG-63 cells (b). (c) Dose-dependent and time-dependent effect of busulfan on the activation of miR-429. (nih.gov)
- Kinetics-based dose targeting is often conducted in hematopoietic cell transplant (HCT) patients conditioned with intravenous (IV) or oral busulfan to lower rates of rejection, nonrelapse mortality, and relapse. (cdc.gov)
Intravenous Busulfan6
- Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial," Cancer , vol. 121, no. 4, pp. 562-569, 2015. (hindawi.com)
- Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination," Biology of Blood and Marrow Transplantation , vol. 17, no. 1, pp. 117-123, 2011. (hindawi.com)
- Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma. (centerwatch.com)
- Personalizing intravenous busulfan doses to a target plasma concentration at steady state ( C ss ) is an essential component of hematopoietic cell transplantation (HCT). (aacrjournals.org)
- The study included 239 participants - both children and adults - who underwent allo-HCT with intravenous busulfan between July 2011 and July 2016 at the University Medical Center in Utrecht, Netherlands. (oncologynurseadvisor.com)
- Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. (duke.edu)
Injection25
- These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. (nih.gov)
- See full prescribing information for BUSULFAN INJECTION. (nih.gov)
- Seizures: Initiate anticonvulsant prophylactic therapy prior to treatment with Busulfan Injection. (nih.gov)
- Drugs that Increase Busulfan Injection Clearance: Phenytoin. (nih.gov)
- Busulfan Injection causes severe and prolonged myelosuppression at the recommended dosage. (nih.gov)
- SunGen Pharma announced the launch of Busulfan injection, the second product launch through their joint venture Peterson Athenex with Athenex (ATNX). (thefreedictionary.com)
- Busulfan injection is given as an infusion into a vein in your upper chest (central IV). (drugs.com)
- Appropriate studies have not been performed on the relationship of age to the effects of busulfan injection in the pediatric population. (mayoclinic.org)
- Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of busulfan injection in the elderly. (mayoclinic.org)
- Busulfan (injection) is an alkylating agent that is FDA approved for the treatment of chronic myelogenous leukemia . (wikidoc.org)
- Male 4-week-old C57BL/6J mice were administered a single intraperitoneal injection of busulfan, and they were then fed a normal diet for 60 days and then a TJ107 diet or TJ107-free normal diet for another 60 days. (mdpi.com)
- Risk Summary Busulfan Injection can cause fetal harm when administered to a pregnant woman based on animal data. (myhealthbox.eu)
- Busulfan Injection is distributed as a unit carton of eight vials NDC 16729-351-92. (myhealthbox.eu)
- Unopened vials of Busulfan Injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time. (myhealthbox.eu)
- Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. (myhealthbox.eu)
- Busulfan Injection is a cytotoxic drug. (myhealthbox.eu)
- Why is busulfan injection medication prescribed? (ndclist.com)
- Physician reviewed busulfan (oral/injection) (oral/injection) patient information - includes busulfan (oral/injection) description, dosage and directions. (usarx.com)
- What Is Busulfan Injection Used For? (emedtv.com)
- Interested in a Discount on Busulfan Injection? (emedtv.com)
- How Busulfan Injection works, side effects, interactions and precautions. (navigatingcare.com)
- Busulfan injection may cause seizures during therapy with the medication. (navigatingcare.com)
- Your doctor will give you another medication to help prevent seizures before and during therapy with busulfan injection. (navigatingcare.com)
- The second group received double doses of busulfan with 21 days interval and their testes were removed on day 35 after the second injection. (iranjournals.ir)
- In conclusion, two doses of busulfan injection with 21 days interval produced an appropriate experimental model of induced azoospermia with comparable stereological indices of seminiferous tubules in rat. (iranjournals.ir)
Total body irradi2
- PURPOSE: This phase I/II trial is studying the side effects of giving busulfan and fludarabine together with total-body irradiation and to see how well they work in treating patients who are undergoing a donor stem cell transplant for hematologic cancer. (clinicaltrials.gov)
- 60 years with AML in first complete remission (CR1), that had received an alloSCT following NMA conditioning, i.e. either fludarabine/busulfan (FB2) or fludarabine/total-body-irradiation-2Gy (FluTBI2Gy). (rug.nl)
Doses of busulfan2
- another (GSK) lists concurrent use of multiple alkylating agents, or total doses of busulfan in excess of 16 mg/kg, as possible risk factors. (pocketdrugguide.com)
- 7 Also, single doses of busulfan can permanently sterilize mice at non-lethal doses and cause long-term morphological damage to sperm produced by surviving spermatogonia. (iranjournals.ir)
Regimen21
- Patients will undergo a conditioning regimen administration with busulfan intravenously for four days to achieve myeloablation prior to the transplant. (thefreedictionary.com)
- In the pre-engraftment period, diarrhea occurs mostly due to mucosal damage caused by the conditioning regimen, such as alkylating agents, busulfan , and combination regimens or radiotherapy (7). (thefreedictionary.com)
- HOUSTON - Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) about to undergo allogeneic hematopoietic cell transplantation (HSCT), say German researchers reporting results from a phase 3 study. (medscape.com)
- The results showed that not only was a treosulfan-based regimen noninferior to one containing busulfan in terms of event-free survival, but that it was associated with significantly improved overall survival and complete donor-type chimerism. (medscape.com)
- The patients were randomly assigned in a 1:1 fashion to a treosulfan- or busulfan-based reduced intensity conditioning regimen, with the primary objective being to show at least the noninferiority of the treosulfan-based regimen in terms of event-free survival. (medscape.com)
- The final analysis set consisted of 283 patients who received the busulfan-based regimen and 268 who were treated with treosulfan prior to HSCT. (medscape.com)
- Beelen reported that the rates of early adverse events were comparable between the treosulfan and busulfan groups, whether looking at all grades, grades III-IV, or regimen-related grade III-IV events. (medscape.com)
- Patients given a treosulfan-based regimen prior to HSCT were significantly more likely to achieve complete hematopoietic chimerism after transplantation than those treated with a busulfan-based regimen, at 93.2% vs 83% (adjusted P = .0159). (medscape.com)
- The conditioning regimen consists of the following drugs: Busulfan and Clofarabine. (clinicaltrials.gov)
- The busulfan half-life and elimination constant were relatively stable throughout the dosing regimen (Table 1). (aacc.org)
- To describe the plasma pharmacokinetics of busulfan when administered intravenously in this regimen. (clinicaltrials.gov)
- Here, we describe the results of a prospective study of HSCT in 22 patients with GATA2 deficiency using a busulfan-based conditioning regimen. (unboundmedicine.com)
- Nonmyeloablative-conditioning regimen: Patients receive busulfan IV on day -5 and fludarabine IV over 30 minutes on days -4 to -2. (clinicaltrials.gov)
- I. To compare progression free survival of two schedules of venetoclax, timed sequential busulfan, cladribine and fludarabine conditioning regimen in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). (centerwatch.com)
- In this study we will be comparing in a randomized fashion the standard regimen to a regimen of fludarabine, busulfan and TBI. (aamds.org)
- Busulfan is a chemotherapeutic agent used as a component in a myeloablative preconditioning regimen before hematological stem cell transplantation. (labroots.com)
- This is a prospective study using oral lorazepam together with busulfan-based conditioning regimen in 30 children undergoing hematopoietic stem cell transplantation. (mysciencework.com)
- Of the many drugs that can be used in a preparative regimen, busulfan is the only one that requires therapeutic drug monitoring. (insight-rx.com)
- Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. (duke.edu)
- We have conducted a phase II trial exploring the combination of busulfan (16 mg/kg) and etoposide (60 mg/kg) in an attempt to improve antitumor efficacy using this novel preparative regimen. (duke.edu)
- The use of nucleoside analogs such as fludarabine (Flu) in combination with i.v. busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). (duke.edu)
Side effects of busulfan1
- You will also receive other medicines to help prevent certain side effects of busulfan. (drugs.com)
Patients42
- Find Clinical Trials for Busulfan - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
- The researchers compared the effect of treosulfan/ fludarabine regimens with those containing busulfan/fludarabine prior to HSCT in more 550 patients with AML or MDS who were either aged 50 to 70 years or who had comorbidities. (medscape.com)
- Patients given treosulfan were more likely to have AML (70.5%) than MDS (29.5%), but the spread was more even in the busulfan group, at 57.5% with AML and 42.5% with MDS. (medscape.com)
- A similar pattern was seen for serious adverse events, although treosulfan patients had more life-threatening serious adverse events than those given busulfan, at 4.8% and 2.8%, respectively, and had more fatal events, at 3% vs 2.1%, respectively. (medscape.com)
- Patients who are pregnant or are trying to become pregnant should notify their physician before taking busulfan (or any chemotherapy medication). (encyclopedia.com)
- If nausea and vomiting are a problem, patients can be given medications known as antiemetics before receiving busulfan to help prevent or decrease these side effects. (encyclopedia.com)
- Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may have harmful affects on the developing fetus. (cancerquest.org)
- Busulfan can cause interstitial pneumonitis, as such patients should be monitored for pulmonary issues. (cancerquest.org)
- There is limited information regarding Off-Label Guideline-Supported Use of Busulfan in adult patients. (wikidoc.org)
- The effectiveness of busulfan in the treatment of CML has not been specifically studied in pediatric patients. (wikidoc.org)
- Absolute neutrophil counts dropped below 0.5×109/L at a median of 4 days post-transplant in 100% of patients treated in the busulfan clinical trial. (wikidoc.org)
- Patients receive intrathecal busulfan twice a week, at least 3 days apart, for 2 weeks. (knowcancer.com)
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. (sigmaaldrich.com)
- The efficacy of busulfan in patients with advanced PV or ET refractory or intolerant to hydroxyurea was assessed in 36 patients (PV n = 15, ET n = 21) treated for a median of 256 days. (sigmaaldrich.com)
- Time to CHR was shorter in patients treated with ≥14 mg of busulfan per week than with lower doses (141 versus 336 days, p = 0.01). (sigmaaldrich.com)
- Busulfan was stopped in 27 patients (75 %) due to CHR achievement in 18 cases (67 %), hematological toxicity in 8 cases (30 %), and disease transformation in 1 case. (sigmaaldrich.com)
- To assess the non-relapse mortality 1-year after conditioning with busulfan and fludarabine/TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease. (clinicaltrials.gov)
- ARM I: Patients receive venetoclax orally (PO) once daily (QD) on days -22 to -3 and busulfan intravenously (IV) over 3 hours on days -13 and -12. (centerwatch.com)
- Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3. (centerwatch.com)
- From July 1983 to January 1991, 441 CML patients were randomized to receive hydroxyurea or busulfan. (uni-bonn.de)
- The median survival of the busulfan treated Philadelphia-positive patients is 45.4 months and of the hydroxyurea group 58.2 months (P = .008). (uni-bonn.de)
- The 23 patients with primary hydroxyurea had a median survival of 5.6 years, the 41 patients with primary busulfan therapy a median survival of 2.7 years (P = .02). (uni-bonn.de)
- The combination of fludarabine and busulfan is the current standard of care for patients with myeloid malignancies (AML, CML and other myeloproliferative disorders, or MDS) undergoing allogeneic transplantation at HUMC. (aamds.org)
- How the Busulfan testing improved the management of Bone Marrow Transplant Patients? (labroots.com)
- The TDM and timely plasma concentration reporting of Busulfan would provide an improvement in the quality-of-care for BMT patients. (labroots.com)
- Identify our purpose to measure Busulfan in BMT patients' samples. (labroots.com)
- Researchers compared models for determining cumulative exposure of busulfan in adult and pediatric patients receiving the drug prior to allo-HCT. (oncologynurseadvisor.com)
- Therapeutic drug monitoring may prevent severe under and/or over exposure of busulfan in patients undergoing allo-HCT, according to study results presented at ESMO Congress 2019 in Barcelona, Spain. (oncologynurseadvisor.com)
- Patients received busulfan daily for 4 consecutive days, and busulfan levels were measured on days 1 and 4. (oncologynurseadvisor.com)
- Pediatric patients received a therapeutic drug monitoring aiming at a cumulative AUC of Busulfan between 45 to 65 mg/L x h. (aspergillus.org.uk)
- Two patients with a low cumulative AUC for Busulfan under 45 mg/L x h had autologuous reconstitution. (aspergillus.org.uk)
- Busulfan is a medication used in the management and treatment of allogeneic hematopoietic progenitor cell transplantation specifically for patients with chronic myelogenous leukemia. (statpearls.com)
- This activity reviews the indications, action, and contraindications for busulfan as a valuable agent in the therapy for allogeneic hematopoietic progenitor cell transplantation specifically for patients with chronic myelogenous leukemia and other disorders when applicable. (statpearls.com)
- It is estimated that this type of complication after allo-HSCT was observed in 0-70% of cases, and the risk of these adverse events increases in the group of patients with liver damage, in which myeloablative chemotherapy or busulfan therapy was used [25]. (thefreedictionary.com)
- OBJECTIVE: To review the current published studies evaluating the pharmacokinetics, clinical efficacy, safety, and toxicity of busulfan in pediatric and adult patients. (elsevier.com)
- DATA SYNTHESIS: Busulfan has been used widely at conventional dosages (1-12 mg/d) for the treatment of patients with chronic myelogenous leukemia (CML). (elsevier.com)
- CONCLUSIONS: Busulfan is a useful, sufficiently safe drug in the treatment of patients with CML. (elsevier.com)
- At higher dosages, busulfan is a fundamental part of myeloablative therapies for patients undergoing BMT. (elsevier.com)
- Busulfan is less effective in patients without the Philadelphia chromosome. (rxwiki.com)
- Busulfan is a prescription medication used in combination with other medications to destroy bone marrow and cancer cells in preparation for a bone marrow transplant in patients with chronic myelogenous leukemia , or CML. (rxwiki.com)
- This is a multicenter retrospective comparison of 2 myeloablative conditioning regimens in 454 patients with acute myeloid leukemia (AML) in remission: busulfan (4 days) and fludarabine (BUFLU) versus thiotepa, busulfan, and fludarabine (TBF). (elsevier.com)
- The average (± standard deviation) busulfan clearance was 3.2 ± 0.56 mL/min/kg in the separate population of 95 patients who received oral busulfan and 103 ± 24 ml/min/m(2) in the 57 patients who received IV busulfan. (cdc.gov)
Transplantation13
- In this research study, the investigators are looking to see how well this new combination of busulfan and clofarabine works in reduced intensity allogeneic stem cell transplantation. (clinicaltrials.gov)
- Busulfan should be administered under the supervision of a qualified physician experienced in hematopoietic stem cell transplantation . (wikidoc.org)
- The following warnings pertain to different physiologic effects of busulfan in the setting of allogeneic transplantation . (wikidoc.org)
- Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. (nih.gov)
- Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation," International Journal of Hematology , vol. 93, no. 4, pp. 509-516, 2011. (hindawi.com)
- Ligand is developing a novel Captisol®-based formulation of Busulfan for use as a conditioning agent prior to hematopoietic stem cell transplantation. (ligand.com)
- Prior to allogenic hematopoietic cell transplantation (allo-HCT), the drug busulfan needs to accumulate to a given therapeutic range of 80-100 mg*hr/L. However, there is known to be within-person variability in how quickly busulfan is cleared from the body. (oncologynurseadvisor.com)
- Boss J, Langenhorst J, Lalmohamed A, Van Der Linden P, Boelens JJ, Van Maarseveen E. The influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation. (oncologynurseadvisor.com)
- Slattery JT, Risler LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. (springer.com)
- busulfan monitoring in bone marrow transplantation), a few calibration measurements that could be collected at random instead of the current strict timing required for current TDM would be a welcome change. (thefreedictionary.com)
- STUDY SELECTION: Emphasis was placed on pharmacologic studies and clinical trials involving busulfan therapy both in myeloproliferative disorders and in conditioning regimens for autologous or allogeneic bone marrow transplantation. (elsevier.com)
- Busulfan treatment is followed by bone marrow transplantation (BMT), with T-cell depleted donor bone marrow bearing a different congenic marker (CD45.2) to that of the host mouse (CD45.1). (bio-protocol.org)
- Busulfan is also used during preparation for stem cell transplantation . (high-kick.ru)
Therapeutic8
- The target area under the plasma concentration vs time curve (AUC) for busulfan was set at 950 μmol · L−1 · min−1, near the low end of the therapeutic interval of 900-1350 μmol · L−1 · min−1. (aacc.org)
- The target area under the plasma concentration vs time curve (AUC) for busulfan was set at 950 µmol · L-1 · min-1, near the low end of the therapeutic interval of 900-1350 µmol · L-1 · min-1. (aacc.org)
- Supplementation of TJ107 can completely recover the injured seminiferous epithelium via normalization of the macrophage migration and reduction of the expressions of Tool-like receptor (TLR) 2 and TLR4, suggesting that TJ107 has a therapeutic effect on busulfan-induced aspermatogenesis. (mdpi.com)
- Parenteral administration of Busulfan (BU) conquers the bioavailability and biovariability related issues of oral BU by maintaining the plasma drug concentration in therapeutic range with minimal fluctuations thereby significantly reducing the side effects. (ovid.com)
- We strongly advocate for the use of a [pharmacokinetic] model aided therapeutic drug monitoring anticipating a decrease in busulfan clearance," write the researchers. (oncologynurseadvisor.com)
- Furthermore, Hachimijiogan and/or Hochuekkito were already determined in busulfan-treatment induced aspermatogenesis in mice and showed the different therapeutic effect on reproductive toxicities. (nii.ac.jp)
- At InsightRX, we're especially interested in therapeutic drug monitoring related to busulfan and vancomycin, two drugs for which we offer precision dosing support . (insight-rx.com)
- Monitoring busulfan exposure using therapeutic drug monitoring is an effective way to mitigate the risk of busulfan toxicity, given its status as a DNA alkylating chemotherapy agent and the known risk of pulmonary toxicity . (insight-rx.com)
Pharmacokinetics1
- As the pharmacokinetics and metabolism of busulfan is further understood, there is great potential for improving treatment outcome. (elsevier.com)
Myeloablative3
- At the American Association for Cancer Research annual meeting this month, Vince Ammoscato, Vice President of Operations at Ash Stevens, Inc. will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). (prweb.com)
- Vince Ammoscato, Vice President of Operations at Ash Stevens Inc. (ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). (prweb.com)
- However, some do not consider the routine use of prophylactic antiepileptics justified, and the potential for phenytointo increase the metabolism of busulfan, thereby possibly decreasing its myeloablative efficacy, has been pointed out. (pocketdrugguide.com)
Seizures7
- Toxicity may include interstitial pulmonary fibrosis ("busulfan lung"), hyperpigmentation, seizures, hepatic (veno-occlusive disease) (VOD) or sinusoidal obstruction syndrome (SOS), emesis, and wasting syndrome. (wikipedia.org)
- Seizures and VOD are serious concerns with busulfan therapy and prophylaxis is often utilized to avoid these effects. (wikipedia.org)
- Levetiracetam, has shown efficacy for the prophylaxis against busulfan-induced seizures. (wikipedia.org)
- Benzodiazepines can also be used for busulfan-induced seizures. (wikipedia.org)
- You may also receive medicines to help prevent seizures after using busulfan. (mayoclinic.org)
- Relationships between toxicity (principally neutropenia, hepatic veno-occlusive disease, incidence of seizures) and drug exposure were found for busulfan. (elsevier.com)
- Clobazam has been suggested as an alternative to phenytoin for prophylaxis of busulfan-induced seizures. (pocketdrugguide.com)
Stop taking b2
- Do not stop taking busulfan without talking to your doctor. (medlineplus.gov)
- Do not stop taking busulfan without speaking with your doctor first. (high-kick.ru)
Toxicity of busulfan1
- Review select appropriate monitoring and toxicity of busulfan. (statpearls.com)
Drugs5
- Busulfan tablets are also used in combination with other drugs to destroy the bone marrow and cancer cells in preparation for a bone marrow transplant. (medlineplus.gov)
- A total of 306 drugs (1693 brand and generic names) are known to interact with busulfan . (drugs.com)
- Busulfan a member of the group of chemotherapy drugs known as alkylating agents. (encyclopedia.com)
- Interestingly, the use of other drugs, such as paracetamol and anticonvulsants, predicted the decline in busulfan clearance over time. (oncologynurseadvisor.com)
- Busulfan belongs to a group of drugs called alkylating agents. (rxwiki.com)
Medication2
- Also tell your doctor if you have taken busulfan before, but your cancer did not respond to the medication. (medlineplus.gov)
- Busulfan may also be used for purposes not listed in this medication guide. (drugs.com)
Take busulfan7
- If you take busulfan with other medications that may cause a low blood count, the side effects of the medications may be more severe. (medlineplus.gov)
- Take busulfan at around the same time every day. (medlineplus.gov)
- Take busulfan exactly as directed. (medlineplus.gov)
- Can I take Busulfan (Apotex) in sport? (healthdirect.gov.au)
- Take Busulfan exactly as directed by your doctor or according to the instructions on the label. (mims.com)
- You can take busulfan tablets before or after meals. (high-kick.ru)
- You may need to take busulfan for several weeks or months. (high-kick.ru)
Quantification of Busulfan in plasma1
- A liquid chromatography-tandem mass spectrometry method for rapid and accurate quantification of Busulfan in plasma was developed and validated in the Department of Chemistry at Baptist Hospital of Miami. (labroots.com)
Regimens2
- Rates of primary and secondary graft failure were lower with treosulfan-based treatment than busulfan-based regimens (3% vs 0.4%), which was driven by no secondary graft failures with treosulfan. (medscape.com)
- Busulfan is an anti-cancer chemotherapeutic drug and is often used as conditioning regimens prior to bone marrow transplant for treatment of chronic myelogenous leukemia. (mdpi.com)
CONTRAINDICATIONS1
- Describe the adverse effects and contraindications of busulfan. (statpearls.com)
Bone7
- Busulfan can cause a severe decrease in the number of blood cells in your bone marrow. (medlineplus.gov)
- Busulfan, when used for bone marrow transplants, is dosed by patient body weight. (encyclopedia.com)
- Nausea, vomiting, loss of appetite, mouth sores, and diarrhea are rare side effects from busulfan at normal doses, but are common at the higher doses used for bone marrow transplant. (encyclopedia.com)
- The most common adverse effect of busulfan is bone marrow depression which results in altered blood cell counts. (cancerquest.org)
- Busulfan is a commonly used antineoplastic agent to condition/ablate bone marrow cells before hematopoietic stem cell transplant. (springer.com)
- The major adverse effect of busulfan with standard doses is bone-marrow depression, manifest as leucopenia, thrombocytopenia, and sometimes, anaemia. (pocketdrugguide.com)
- The nadir of the granulocyte count usually occurs after about 10 to 30 days with recovery occurring over up to 5 months, but busulfan has sometimes caused irreversible or extremely-prolonged bone-marrow depression. (pocketdrugguide.com)
Oral9
- Oral bioavailability of busulfan shows a large interindividual variation. (wikipedia.org)
- Take the busulfan oral tablet with a full glass of water. (drugs.com)
- Busulfan is usually administered as an oral tablet. (cancerquest.org)
- While intravenous (IV) formulations of busulfan are now available and have lower incidences of toxicity and treatment related mortality compared to oral dosing, it still displays large pharmacokinetic variability. (springer.com)
- Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. (cdc.gov)
- Oral busulfan clearance was associated with GSTA1 (P = .008) but not GSTM1 (P = .57) genotypes. (cdc.gov)
- However, among the GSTA1 haplotypes (ie, *A*A, *A*B, *B*B), there was significant overlap in the observed oral busulfan clearance and similar rates of achieving the target busulfan exposure. (cdc.gov)
- These data suggest that personalizing either IV or oral busulfan dosing cannot be simplified on the basis of GSTA1 or GSTM1 genotype. (cdc.gov)
- Association of Oral Busulfan Clearance with GSTA1 (panel 3A, P=0.008) but not GSTM1 (panel 3B, p=0.57). (cdc.gov)
Concentration1
- THT+ formation rate increased linearly with busulfan concentration up to its solubility limit for all GST isoforms. (aspetjournals.org)
Chronic myelogen1
- In a randomized multicenter study the influence of hydroxyurea versus busulfan on the duration of the chronic phase and on survival of chronic myelogenous leukemia (CML) was determined. (uni-bonn.de)
Allergic reaction to busulfan1
- Do not use it if you had an allergic reaction to busulfan, or if you are pregnant. (limamemorial.org)
Severe aspermatogenesis after busulfan2
- Tsumura Co., Ltd., Tokyo, Japan) to mice suffering from severe aspermatogenesis after busulfan treatment to determine whether TJ107 can recover spermatogenesis. (mdpi.com)
- Although the damages of spermatogenesis and the testicular immunology after busulfan- or irradiation-treatment are different, Goshajinkigan can completely cure the severe aspermatogenesis after busulfan- or irradiation-treatment in mice. (nii.ac.jp)
Chemotherapeutic1
- Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug's relative low cost. (wikipedia.org)
Byoo SUL fan1
- BUSULFAN (byoo SUL fan) is a chemotherapy drug. (ahealthyme.com)
Treatment14
- Your doctor will order laboratory tests before, during and after your treatment to check your body's response to busulfan to see if your blood cells are affected by this drug. (medlineplus.gov)
- Busulfan is also being studied in the treatment of other types of cancer . (cancer.gov)
- Busulfan was approved by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML) in 1999. (wikipedia.org)
- Before you begin treatment with busulfan, you and your doctor should talk about the benefits this medicine will do as well as the risks of using it. (mayoclinic.org)
- After busulfan treatment, the weight of the testes and the epididymal sperm count progressively decreased in the normal diet group. (mdpi.com)
- These results suggest that busulfan-induced aspermatogenesis is irreversible if appropriate treatment is not administered. (mdpi.com)
- Busulfan is effective as first-line therapy, but there is scarce information on this drug as second-line treatment. (sigmaaldrich.com)
- Journal Article] Male infertility after anticancer treatment and oriental medicine therapy -----Gosha-jinki-gan recovers the intact spermatogenesis in busulfan-induced aspermatogenesis in mice. (nii.ac.jp)
- Garlic (Allium sativum) , a widely distributed medicinal plant, is highly regarded for its medicinal activities including antioxidant property.This study was conducted to assess whether garlic extract could serve as protective agents against testicular toxicity during busulfan treatment in a mice model.Seventy-two adult male mice were randomly divided into nine groups. (iranjournals.ir)
- Rarely, progressive interstitial pulmonary fibrosis, known as 'busulfan lung', can occur on prolonged treatment. (pocketdrugguide.com)
- Testing for the Philadelphia chromosome is done to see whether treatment with busulfan is likely to be effective in treating acute myelogenous leukemia. (rxwiki.com)
- If testing is not done, treatment with busulfan may not be effective. (rxwiki.com)
- Moreover, efficient induction of miR-429 was detected 24 h after busulfan treatment. (nih.gov)
- We found that the five members in the miRNA-200 family were all upregulated after busulfan treatment in both cell lines (Fig. 2a). (nih.gov)
Drug14
- This page contains brief information about busulfan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. (cancer.gov)
- If you have an allergy to busulfan or any other part of this drug. (mskcc.org)
- Busulfan is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. (wikidoc.org)
- Busulfan cancer chemotherapy drug molecule (alkylating agent). (sciencephoto.com)
- Captisol Enabled™ Busulfan has the potential to improve tolerance, which may result in higher drug exposure and longer duration of therapy. (ligand.com)
- There are ten drug master file entries for busulfan. (drugpatentwatch.com)
- Langman L.J., Danso D., Robert E., Jannetto P.J. (2016) High-Throughput Quantitation of Busulfan in Plasma Using Ultrafast Solid-Phase Extraction Tandem Mass Spectrometry (SPE-MS/MS). In: Garg U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. (springer.com)
- A vertically integrated pharmaceutical company heavily focused on research & development and in manufacturing drug intermediates, Active Pharmaceutical Ingredients (API) & finished formulations is searching for suppliers of Busulfan and L-Asparaginase injections. (pharmacompass.com)
- Busulfan with NDC 0409-1112 is a a human prescription drug product labeled by Hospira, Inc.. The generic name of Busulfan is busulfan. (ndclist.com)
- busulfan is a topic covered in the Davis's Drug Guide . (unboundmedicine.com)
- Medicine Central , im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/51117/all/busulfan. (unboundmedicine.com)
- This is not a complete list of busulfan drug interactions. (rxwiki.com)
- The conditioning drug busulfan is used to ablate host haematopoietic stem cells while leaving the peripheral immune system intact. (bio-protocol.org)
- 2004). To avoid the perturbation of immune homeostasis caused by irradiation, we turned our attention to the conditioning drug busulfan. (bio-protocol.org)
Glutathione5
- Concomitant use of acetaminophen within 72 hours of busulfan use can reduce busulfan clearance (resulting in increased busulfan AUC), as acetaminophen is also metabolized via glutathione and may deplete stores. (wikipedia.org)
- Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase. (medicinenet.com)
- Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. (aspetjournals.org)
- Busulfan is eliminated by glutathione S-transferase (GST)-catalyzed conjugation with glutathione (GSH). (aspetjournals.org)
- Using the candidate gene approach, the authors evaluated whether busulfan clearance was associated with polymorphisms in the genes regulating the predominant metabolizing enzymes involved in busulfan conjugation, specifically glutathione S-transferase (GST) isoenzymes A1 (GSTA1) and M1 (GSTM1). (cdc.gov)
Phenytoin1
- Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). (wikipedia.org)
Irradiation1
- Male mice were received busulfan or irradiation and then fed on the Goshajinkigan-including diet. (nii.ac.jp)
Exposure to busulfan1
- We also used gas chromatography-electron capture detection and pharmacokinetic models to assess whether excessive exposure to busulfan correlates with an increased risk of VOD. (nih.gov)
Clearance of busulfan1
- Decreased clearance of busulfan was observed with concomitant use with deferasirox. (medicinenet.com)
Therapy with busulfan1
- Haemorrhagic cystitis occurred in a patient who had received prolonged therapy with busulfan. (pocketdrugguide.com)
Interact with busulfan2
- Many other medications may also interact with busulfan, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)
- Show all medications in the database that may interact with busulfan. (drugs.com)
Fludarabine and busulfan1
- RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. (clinicaltrials.gov)
Medicines2
- Busulfan belongs to the group of medicines known as alkylating agents. (mayoclinic.org)
- Some medicines can affect how busulfan works. (limamemorial.org)
Pregnant6
- If you become pregnant while taking busulfan, call your doctor immediately. (medlineplus.gov)
- If you are a woman, do not use busulfan if you are pregnant. (drugs.com)
- It is important that you do not get pregnant while being treated with Busulfan. (mims.com)
- you should know that busulfan may interfere with the normal menstrual cycle (period) in women, may stop sperm production in men, and may cause infertility (difficulty becoming pregnant). (navigatingcare.com)
- Women should not get pregnant while on busulfan. (rxwiki.com)
- It is important that you do not get pregnant or father a child while you are taking busulfan. (high-kick.ru)
Stem1
- Busulfan is primarily used as a preparative agent prior to hematopoietic stem cell transplant (HCT). (insight-rx.com)
Mice8
- Slight decrease in Kitlg mRNA expression has also been observed in mice treated with busulfan , albeit this reduction was not statistically significant In contrast with GDNF and FGF2, KITLG is believed to be involved in SSCs differentiation. (thefreedictionary.com)
- Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. (myhealthbox.eu)
- Ameliorative effect of Allium sativum extract on busulfan-induced oxidative stress in mice sperm', Veterinary Research Forum , 9(3), pp. 265-271. (iranjournals.ir)
- Following euthanasia, blood samples and epididymal sperm were collected.The busulfan-treated group showed significant decreases in sperm qualityparameters, and serum levels of testosterone, LH and FSH was observed in the busulfan-treated mice. (iranjournals.ir)
- In addition, the TAC levels and antioxidant enzymes activities were reduced and malondialdehyde (MDA) levels were increased in the busulfan-treated mice. (iranjournals.ir)
- Based on our results, garlic has antioxidant effects against busulfan-induced testicular damages in mice. (iranjournals.ir)
- Busulfan-treated mice exhibited a marked increase in apoptosis and a decrease in testis weight. (iranjournals.ir)
- 8 On the other hand, in molecular mechanism, it has been demonstrated that increased depletion of male germ cells in the busulfan-treated mice is mediated by loss of c-kit/SCF signaling, not by p53- or Fas/FasL -dependent mechanisms. (iranjournals.ir)
Intravenously1
- Busulfan comes as a solution (liquid) to be given intravenously (into a vein) over 2 hours by a doctor or nurse in a medical facility. (navigatingcare.com)
Tablets1
- tell your doctor and pharmacist if you are allergic to busulfan, any other medications, or any of the ingredients in busulfan tablets. (medlineplus.gov)
Taken busulfan2
- Alert your doctor if you have previously taken Busulfan and it did not work. (mims.com)
- Busulfan toxicity involving the liver was also reported in a patient who had taken busulfan for 54 months, while hepatitis possibly associated with busulfan therapy has also been described. (pocketdrugguide.com)
Standard busulfan1
- Damage to nerves and nervous system tissues is uncommon with standard busulfan therapy. (encyclopedia.com)